Recently, a potent STAT3 degrader SD-36 based on the proteolysis targeting chimera (PROTAC) concept, utilizing a ligand for cereblon/cullin 4A E3 ligase and a peptidomimetic STAT3 SH2 domain inhibitor, was discovered and showed potent anti-tumor activities in blood cancer 39. This evidence concerns the gene STAT3 and hematopoietic and lymphoid system neoplasm.